CRISPR QC

Join us in celebrating the recognition of CQC co-founder and scientific advisor, Dr. Kiana Aran, as a winner of the Sony Women in Technology Award with Nature! This award highlights the importance of her groundbreaking work in bioengineering and CRISPR-powered electronic diagnostics. 🧬 "Aran's achievements and vision in the field of bioengineering are impressive with a clear pathway to significant real-world impact for patients," noted the distinguished judging panel. Beyond her research, Dr. Aran is a champion of women in science through mentorship and advocacy. Get the full story below! https://lnkd.in/gba9ASFx #WomenInSTEM #Innovation #Bioengineering

We're feeling energized by the incredible conversations and breakthroughs shared at the Genome Editing Therapeutics Summit in Boston! The pace of innovation in gene editing continues to excite us, and we're seeing firsthand how QC matters more than ever as CRISPR therapies move toward the clinic. #CRISPR #GeneTherapy #Biotech #Innovation #BostonBiotech 

CRISPR QC is a proud sponsor of the Genome Editing Therapeutics Summit taking place this week in Boston, MA! 🧬 This is the industry's premier summit for spearheading the development, application, and delivery of novel gene editing technologies; we're excited to connect with fellow innovators and discuss how robust QC processes can accelerate the development of more effective therapies. Are you attending? Stop by our booth to learn about our cutting-edge CRISPR Analytics Platform.

CQC co-founder Dr. Kiana Aran has been shortlisted for the 2025 Sony Women in Technology Award with Nature! This competitive program highlights researchers from across the globe who are spearheading technological breakthroughs for the betterment of society.  🧬🌟 Dr. Aran is being recognized for her innovative work with graphene biosensors and CRISPR technology, her dedication to mentoring female engineers, her entrepreneurial spirit, and driving international scientific collaboration. Winners will be announced February 5, 2025 in Tokyo. Learn more: https://lnkd.in/gkb9JXYH #WomenInSTEM #Biotechnology #Innovation #CRISPR #PrecisionMedicine

🤝 Xcellerant Ventures and CRISPR QC: A Powerful Connection Made at a YSV Summit🤝 Xcellerant Ventures led by General Partners John Shufeldt, Chris Yoo and Douglas Sylvester is making waves in the world of early-stage investment by focusing on high-impact healthtech, medtech, and biotech startups. Their mission is to drive transformative solutions that enhance healthcare quality, accessibility, and efficiency while keeping costs under control. By zeroing in on companies that solve real-world healthcare challenges, Xcellerant is contributing to the improvement of care delivery and the sustainability of the healthcare system. 🔍 What sets Xcellerant Ventures apart is their unique, founder-centric approach. Beyond just providing capital, their managing partners—who bring a wealth of experience from multiple successful exits in the health and medtech industries—are actively involved in guiding and mentoring their portfolio companies. This hands-on support goes beyond typical VC involvement, giving founders access to deep industry expertise and connections. Additionally, Xcellerant is committed to an inclusive innovation ecosystem, prioritizing underrepresented founders and startups that are often overlooked by traditional investors. Their investment strategy focuses on revenue-generating companies with clear regulatory pathways, allowing for faster exits and lower risk. A recent example of their impactful investment approach is their lead role in the Series A round for CRISPR QC led by CEO Ross Bundy. This biotech company is advancing gene-editing precision through its innovative platform, which has far-reaching applications in personalized medicine and agriculture. CRISPR QC’s technology exemplifies Xcellerant’s dedication to supporting pioneering solutions with the potential to change industries and improve lives. Through their investments, Xcellerant Ventures is not only supporting groundbreaking technologies but also building a more inclusive, accessible future in healthcare innovation. 📢 Join active, expert investors like the Xcellerant Ventures team at the 2024 New England Venture Summit on December 10th-11th in Boston! 🔗 Register at https://lnkd.in/dqWM4Ng3

Lots of groundbreaking, life-saving work being done in the cell and gene therapy space, and we're excited to collaborate with the best and brightest in the field at the upcoming Cell & Gene Meeting on the Mesa. Our CEO, Ross Bundy and CCO, Tim Cloutier, PhD are headed out to Phoenix, AZ on October 7-9 -- let's connect and push your CRISPR solutions forward, together.

We’re wrapping up our week in Boston for the CRISPR-Based Therapy Analytical Development Summit! It’s been inspiring sharing our developments and learning from other key players in this dynamic field. We’re humbled to be sponsoring this critical industry event. A big thank you to everyone we connected with—we’re excited to see how the future of CRISPR therapies continues to evolve! #CRISPR #GeneEditing #Biotech #Innovation #Boston #Summit #ScientificResearch #QualityControl #Therapeutics

come by our table to discuss some of the best and latest analytical capabilities on the market for gene editing! CRISPR QC #crispr #geneediting

We will be sponsoring the CRISPR-Based Therapy Analytical Development Summit this week in Boston, MA! This is an exciting way for us to keep our finger on the pulse of this rapidly-advancing industry. All details below: https://lnkd.in/gD_XdbQ4